4105.05
CP101, AN INVESTIGATIONAL ORALLY ADMINISTERED MICROBIOME THERAPEUTIC, WAS EFFECTIVE FOR PREVENTION OF RECURRENT C. DIFFICILE INFECTION: RESULTS FROM OPEN-LABEL PRISM-EXT TRIAL
Date
May 23, 2022
Explore related products in the following collection:
